Skip to main content

Urinary micro RNA pattern as marker for early breast cancer diagnosis

Ref-Nr: TA-ZEE20150317


Non-invasive, hazard-free detection of early breast cancer in urine


Since recent studies revealed the feasibility to detect blood-based microRNAs (miRNAs, miR) in breast cancer (BC) patients a new field has been opened for circulating miRNAs as potential biomarkers in BC. In this pilot study, we evaluated to our knowledge for the first time whether distinct pattern of urinary miRNAs might be also applicable as innovative biomarkers for BC detection.


Breast cancer (BC) represents the most frequent malignant disease in women worldwide. In Germany 72.000 cases are diagnosed each year (worldwide appr. 1.2 million women). Detection of BC is based on clinical symptoms (e.g. lumps) or established screening programs for detection of early disease by mammography. Early detection is crucial for improved curation rates and minimization of therapeutical procedures (surgery, chemotherapy). However, screening with X-rays is controversially discussed and participation rates are suboptimal due to the exposure to radiation doses and their potential harmful biological effects. MicroRNAs (miRNAs) are small (< 30 basepairs) non-coding RNAs with multiple crucial functions also in breast cancer as tumor promoting as well as tumor suppressing factors. We developed an unique urine-based miRNA assay (9 specific miRNAs) to detect early, primary breast cancer.


Urinary miRNA expression levels of nine BC-related miRNAs (miR-21, miR-34a, miR-125b, miR-155, miR-195,
miR-200b, miR-200c, miR-375, miR-451) from 24 untreated, primary BC patients and 24 healthy controls
were quantified by realtime-PCR. The receiver operating characteristic analyses (ROC) and logistic regression were calculated to assess discriminatory accuracy.


  • Quantification of 9 miRNAs in midstream urine (5ml) with a specific expression pattern to detect early breast cancer
  • High sensitivity and specificity (detection rate: > 90%)
  • Non-invasive and hazard-free


  • Screening for breast cancer as part of an innovative multiple step concept to avoid unnecessary diagnostic work up and radiation exposure
  • Tool for follow-up after breast cancer treatment for detection of recurrences
  • Monitoring of treatment response in the neoadjuvant and metastatic setting


Dr. Claudia Skamel
Campus Technologies Freiburg GmbH
Stefan-Meier-Str. 8, D-79104 Freiburg
Tel: +49 (0)761 203-4987
Fax:+49 (0)761 203-5021

Campus Technologies Freiburg GmbH

Dr. Claudia Skamel
+49 (0) 761/203 499
Stefan-Meier-Str. 8
79104 Freiburg




  • EP EP3070178 (A1); anhängig
  • US US2016369352 (A1) anhängig

Angebot Anbieter-Website

Kontakt | Geschäftsstelle

TechnologieAllianz e. V.
Laure Wolkers

c/o PROvendis GmbH
Schloßstr. 11-15
D-45468 Mülheim an der Ruhr